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Abstract
Background: The tuberculin skin test (TST) and interferon-gamma-release-assays (IGRAs) are utilized in screening
programmes for presumed latent tuberculosis infection (LTBI) in health care workers (HCWs). However, inter-test
comparison yields high rates of discordance, which is poorly understood. The aim of the study was therefore to
identify factors associated with discordance amongst HCWs in a TB and HIV endemic setting.
Methods: 505 HCWs were screened for LTBI in South Africa using the TST and two IGRA assays (QuantiFERON-TB-
Gold-In-Tube (QFT-GIT) and TSPOT.TB). Factors associated with discordance were analyzed using a multinomial
logistic regression model.
Results: TST-IGRA discordance was negatively associated with longer duration of employment for both TSPOT.TB
(OR = 0.92; 95% confidence interval (CI) 0.85–0.99) and QFT-GIT (OR = 0.90; 95% CI 0.84–0.96). Marked test discordance
occurred in HIV-infected individuals who were more likely to have TSPOT.TB + ve / TST-ve discordance (OR 4.44; 95%
CI 1.14–17.27) or TSPOT.TB + ve / QFT-GIT-ve test discordance (OR 5.72; 95% CI 1.95–16.78). Those engaged in home
care were less likely to have QFT-GIT + ve/TSPOT.TB -ve / discordance (OR 0.32; 95% CI 0.10–0.95).
Conclusion: The marked TST-IGRA and IGRA-IGRA discordance in HIV-infected individuals suggest greater sensitivity of
TSPOT.TB in immunocompromised persons or potential greater reactivity of TSPOT.TB in this population.
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Background
The diagnosis and management of presumed latent TB
infection (LTBI) form an important strategy in the fight
against TB. The identification of patients with LTBI at
high risk of progression to active tuberculosis is deemed
a research priority [1]. The World Health Organization
(WHO) currently recommends that testing and treat-
ment for LTBI be performed on all HIV positive individ-
uals. This recommendation is extended to populations
deemed at increased risk of TB such as health care
workers (HCWs) in low TB incidence settings only [2].
However, there are considerable differences in screening
guidelines between countries, with limited evidence to
support choice and effectiveness of testing strategies [3].
In South Africa, a high tuberculosis (TB) incidence
country, the prevalence of LTBI in HCWs as measured
by a positive tuberculin skin test (TST) ranges from 48
to 84% while HIV prevalence is > 10% [4]. Despite their
high risk for active TB and increased exposure to TB in
the workplace, screening for LTBI among HCWs is very
limited in practice [5].
Reasons include resource constraints as well as uncer-
tainty about the performance of TST and interferon-
gamma release assays (IGRAs). Stigma may also play a
role – as it is defined as devaluing a social trait or
characteristic which can lead to discrimination of an in-
dividual or group. A diagnosis of tuberculosis through
its association with poverty and HIV in this setting car-
ries with it a considerable degree of stigma. A recent
study of South African HCWs found stigma to be nega-
tively associated with health seeking behavior such as
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screening for TB screening or presenting for Isoniazid
prophylaxis [6].
Despite low quality evidence, IGRAs have been pro-
posed as acceptable alternatives to TST and have been in-
corporated into screening guidelines by WHO [2, 7–9].
These assays react to early secreted antigenic target 6
(ESAT-6) and culture filtrate protein (CFP-10) encoded
within the region of difference (RD1) of the M tuberculosis
genome. Two IGRAs are available: QuantiFERON-TB
Gold-In-Tube (QFT-GIT; format recently changed to
QuantiFERON-TB Gold) (Cellestis Limited, Victoria,
Australia) and TSPOT.TB (Oxford Immunotec, Oxford,
UK). IGRAs have superior specificity and are less affected
by cross reactivity with previous BCG vaccination than
TST [10, 11]. There is marked discordance in test per-
formance between TST and IGRAs. This phenomenon is
partially accounted for by test properties but also appears
to be modified by host, immunological and exposure
factors. The utility of IGRAs in TB endemic settings has
not been shown, and a clearer understanding of factors
associated with discordance should result in a more in-
formed approach to screening strategies. To address this
knowledge gap we determined the occupational and
non-occupational factors associated with TST/IGRA
discordance in HCWs.
Methods
Participants were drawn from five primary healthcare
facilities which provide TB diagnostic and treatment
services, and two secondary level hospitals caring for
patients with complicated, multi-drug-resistant or ex-
tremely drug- resistant TB. Five facilities were located in
the Cape Town township of Khayelitsha, with a TB case
notification rate of over 1600/100000, 70% of which rep-
resents with co-infection with HIV [12].
All participants underwent administration of TST and
venesection for QFT-GIT and T- SPOT.TB. TST was per-
formed using 1 TU dose of PPD RT23 (Statens Serum
Institut, Copenhagen, Denmark). A detailed methods
section has previously been published [13]. The value for
a positive TST was a skin reaction measured as 10mm in
diameter. This relatively high cut-off was used to improve
specificity- as there is near universal vaccination with
BCG given at birth in South Africa. For those who were
HIV-infected a value of 5mm was considered a positive
TST result to counteract a possible anergic effect due to
immunosuppression.
Blood samples for the IGRA assays were drawn con-
currently or within 3 days of administering TST. This
interval has been shown to be sufficiently short to elim-
inate potential boosting [14, 15]. The QFT-GIT test was
considered positive if the interferon- gamma response
minus the nil antigen was ≥0.35 IU/ml. For TSPOT.TB,
the number of IFN-λ spot forming T cells (SFC) per
million peripheral blood mononuclear cells (PBMCs)
was determined using an AIM ELISPOT reader and
Oxford Immunotec software. A cut-off of six or more
spots was treated as a positive result. To minimize
inter-operator and inter-laboratory variability, all assays
were done by one operator. Indeterminate results were
treated as missing data and observations were not used
in the agreement analysis.
Statistical analyses were performed using Stata version
11 (Stata Corp, College Station, Texas). Outcomes in-
cluded agreement between the tests using the kappa
statistic (κ), and factors associated with discordance.
Agreement analyses was performed on baseline results
and has been reported previously [13].
Discordant pairs numbered six in total: TST + ve/
IGRA-ve, TST- ve/IGRA+ve or IGRA+ve/ IGRA-ve. Fac-
tors associated with discordance at baseline were
explored using a series of multinomial logistic regression
models that compared discordant groups with a refer-
ence group displaying perfect agreement (negative and
positive concordance). Discordance was evaluated be-
tween 2 different tests e.g. IGRA and TST or IGRA and
IGRA. The association between each variable and two
potential discordant test outcomes was then evaluated in
one multinomial regression model. A multivariate
analysis adjusting for all variables in the model was con-
ducted. Significant covariates in the model were age,
gender and HIV status. Variables included in the final
model for all three tests were chosen on statistical
significance (p < 0.05) for any of the three tests in
unadjusted analysis, and biological plausibility.
Results
Participants with TST and IGRA assay outcomes
The population eligible for participation were 764
HCWs. Based on voluntary participation, 505 HCWs
were recruited, a 67% participation rate (Fig. 1). Owing
to a higher rate of indeterminate results there were
fewer valid test pairs available for comparison for
TSPOT.TB (n = 450) than for QFT-GIT (n = 482).
Agreement between TST reactions and IGRA assays
Agreement at baseline has previously been reported on
for this study [13]. There was only fair agreement be-
tween TST and the IGRAs, with κ = 0.28 [95% confi-
dence interval (CI) 0.20–0.36] and κ = 0.25 (95% CI
0.18–0.33) for QFT-GIT and TSPOT.TB respectively.
Agreement between the two IGRA assays was moder-
ate with κ = 0.65 (95% CI). Agreement analysis was
performed between the IGRA assays and three different
cut-offs for TST (≥5, ≥ 10 and ≥ 15 mm) without taking
HIV status into consideration and was essentially
unchanged across the different cut points.
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Predictors of discordant test responses
Table 1 presents the results of the multinomial models
used to estimate the relative odds of discordant results
between QuantiFERON-TB Gold-in-tube and tuberculin
skin test. The reference category for all models includes
pairs displaying perfect agreement, with both tests giving
the same result, either positive or negative.
Tables 2 and 3 presents analogous results for the
analysis of discordant results between TSPOT.TB and
tuberculin skin test and between QFT-GIT and
TSPOT.TB, respectively.
BCG
A TST + ve/IGRA-ve discordant test response was more
likely in those with a BCG vaccination scar and signifi-
cantly so for TST + ve/TSPOT.TB-ve. BCG scar positive
Individuals were less likely to have QFT-ve/TSPOT.TB
+ ve discordance.
Fig. 1 Study plan and flow diagram illustrating valid paired tests for the discordance analysis
Table 1 Results of multinomial regression models for discordant QuantiFERON-TB Gold-in-tube and tuberculin skin test at baseline
Positive TST and negative QFT-GIT test result Negative TST and positive QFT-GIT test result
Risk Factor OR (95% CI) N = 112 Adjusted OR (95% CI) N = 24 Adjusted
Older age, per each additional year 0.99 (0.70–1.01) 1.00 (0.97–1.02) 1.01 (0.98–1.05) 1.08 (1.03–1.13) **
Male gender 0.93 (0.57–1.52) 0.75 (0.44–1.28) 1.15 (0.46–2.87) 1.07 (0.38–3.04)
BCG Vaccination scar 1.28 (0.74–2.21) 1.27 (0.69–2.31) 1.06 (0.39–2.92) 0.83 (0.25–2.79)
HIV Positive / reported as positive 1.12 (0.55–2.25) 1.07 (0.47–2.42) 1.97 (0.63–6.16) 2.38 (0.58–9.71)
Previous TB Treatment 1.03 (0.55–1.94) 1.16 (0.57–2.36) 1.34 (0.44–4.09) 0.73 (0.16–3.27)
Symptom screen positive 0.67 (0.40–1.13) 0.59 (0.33–1.04) 1.56 (0.66–3.69) 1.15 (0.42–3.16)
Years in healthcare 0.99 (0.97–1.01) 0.98 (0.95–1.01) 0.94 (0.89–0.99) * 0.90 (0.84–0.96)**
Home care of TB 0.73 (0.31–1.71) 0.70 (0.28–1.72) 0.99 (0.22–4.44) 0.30 (0.04–2.59)
Daily contact with TB patients 0.78 (0.39–1.5) 0.85 (0.40–1.80) 1.12 (0.25–4.99) 2.20 (0.27–17.76)
OR odds ratio, CI confidence interval
*P < 0.05; **P < 0.01; ***P < 0.001
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Length of service
HCWs with more years in healthcare employment were
less likely to have a discordant test (TST-ve/IGRA+ve)
outcome; in other words, TST/IGRA discordance
declined with duration of employment.
HIV status
HIV infected individuals were more likely to test
TSPOT.TB + ve/ TST-ve and TSPOT.B + ve /QFT-GIT-
ve, relative to HIV negative HCWs.
Home-based care
HCWs engaged in home care were less likely to have a
discordant test (TST + ve/ TSPOT.TB-ve) response.
Discussion
This study evaluated factors associated with discordant
test responses for presumed latent TB infection in
healthcare workers in a high TB and HIV prevalence
setting. It found the following factors significantly asso-
ciated with an increased odds of discordance: HIV infec-
tion, long exposure in healthcare environments and
BCG vaccination. The finding of a markedly increased
odds of a discordant test response in HIV-infected
HCWs (OR = 4.44) for TSPOT.TB + ve/TST-ve and (OR
= 5.72) for TSPOT.TB + ve/QFT- GIT-ve suggests that
TSPOT.TB test performance is relatively unimpaired by
HIV infection in this population and is therefore a po-
tentially more sensitive assay than TST for detecting
LTBI in HIV-infected HCWs [16, 17]. A meta- analysis
by Cattamanchi et al. did not show IGRAs as a class to
be consistently more sensitive than TST in HIV-infected
individuals but did conclude that the TSPOT.TB assay
exhibited higher sensitivity and was less affected by im-
munosuppression, than either TST or QFT-GIT [18]. A
subsequent review by Overton et al. similarly concluded
Table 2 Results of multinomial regression models for discordant TSPOT.TB and tuberculin skin test at baseline
Risk Factor Positive TST and negative
TSPOT.TB test result
Negative TST and positive
TSPOT.TB test result
OR (95% CI) N = 126 Adjusted OR (95% CI) N = 20 Adjusted
Older age, per each additional year 0.97 (0.95–0.99) ** 0.97 (0.94–0.99)* 1.00 (0.96–1.04) 1.07 (1.01–1.13)*
Male gender 0.93 (0.58–1.50) 0.72 (0.43–1.21) 1.22 (0.45–3.29) 1.46 (0.45–4.75)
BCG Vaccination scar 1.42 (0.82–2.46) 1.92 (1.02–3.63) * 1.07 (0.34–3.32) 1.04 (0.26–4.17)
HIV Positive/reported as positive 1.03 (0.50–2.11) 0.88 (0.37–2.05) 4.72 (1.64–13.59) ** 4.44 (1.14–17.27)*
Previous TB Treatment 0.88 (0.46–1.68) 1.02 (0.48–2.17) 3.00 (1.09–8.28)* 1.33 (0.35–5.10)
Symptom screen positive 1.05 (0.65–1.68) 1.03 (0.60–1.75) 2.95 (1.18–7.35) * 1.94 (0.64–5.86)
Years in healthcare 0.98 (0.96–1.0) 1.00 (0.97–1.03) CI (0.88 - 0.99)* 0.92 (0.85–0.99)*
Home-care 0.32 (0.11–0.94) * 0.32 (0.10–0.95) * 1.74 (0.48–6.30) 0.63 (0.11–3.56)
Daily contact with TB patient 0.88 (0.45–1.71) 0.94 (0.45–1.98) 2.08 (0.27–16.09) NC
OR odds ratio, CI confidence interval
*P < 0.05; **P < 0.01; ***P < 0.001
Table 3 Results of multinomial regression models for discordant QFT-GIT and TSPOT.TB at baseline
Positive QFT-GIT and negative
TSPOT.TB test result
Negative QFT-GIT and positive
TSPOT.TB test result
Risk Factor OR (95% CI) N = 47 Adjusted OR (95% CI) N = 29 Adjusted
Older age, per each additional year 95% CI ; 0.94 - 0.99) * 0.99 (0.95–1.03) 0.97 (0.92–1.01) 1.03 (0.99–1.08)
Male gender 0.98 (0.50–1.97) 0.98 (0.47–2.05) 1.09 (0.47–2.55) 1.54 (0.57–4.13)
BCG Vaccination scar 0.66 (0.33–1.33) 0.88 (0.37–2.01) 0.54 (0.22–1.15) 0.48 (0.19–1.23)
HIV Positive/reported as positive 1.18 (0.44–3.18) 1.66 (0.53–5.24) 5.11 (2.11–12.33) *** 5.72 (1.95–16.78)**
Previous TB Treatment 0.29 (0.07–1.22) 0.24 (0.05–1.17) 1.34 (0.49–3.67) 0.74 (0.23–2.36)
Symptom screen positive 1.35 (0.70–2.59) 1.48 (0.71–3.08) 1.09 (0.47–2.55) 0.78 (0.29–2.11)
Years in healthcare 0.97 (0.93–1.00) 0.97 (0.93–1.02) 0.97 (0.93–1.01) 0.95 (0.90–1.01)
Home-care 0.26 (0.03–1.94) 0.24 (0.03–1.85) 3.10 (1.17–8.21) * 2.42 (0.77–7.56)
Daily contact with TB patient 0.59 (0.24–1.40) 0.71 (0.27–1.87) 0.64 (0.21–1.94) 1.04 (0.27–4.00)
OR odds ratio, CI confidence interval
*P < 0.05; **P < 0.01; ***P < 0.001
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that the rate of reactivity of both IGRAs and TST was
affected by the level of HIV-associated CD4 T-cell defi-
ciency and that all assays appeared to be affected by the
degree of CD4 T-cell depletion, with the possible excep-
tion of the TSPOT.TB assay [19, 20]. It is noted however
that studies included in the systematic reviews were het-
erogeneous, few performed head to head comparisons
between TST and IGRAs, and there were few studies
specifically evaluating the performance of TSPOT. TB.
As suggested by the epidemiological finding in this
study, the performance of TST and QFT- GIT appears to
be more susceptible to CD4 T cell depletion, manifesting
as anergic TST responses and low-mitogen QFT-GIT re-
sponses with CD4 count acting as an effect modifier.
Overton et al. further conclude that the likelihood of a
positive reaction in the TST or ELISA-based IGRA at
low CD4 levels is negligible.
Alternative explanations for the IGRA-TST and IGRA-
IGRA discordance may include the test format (ELI-
SPOT is a cell-based readout and therefore inherently
more sensitive than ELISA), the use of different test-spe-
cific antigen formulations that may differentially turn on
regulatory (inhibitory) pathways, host factors, strain
type, or likely a combination of these factors [21, 22].
Emerging research suggests that different M. tb strains
differentially regulate host IFN-gamma responses in HIV
negative individuals and that these differences may be a
result of genetic differences in the ESX-1 region. This
could in part explain some of the differences seen in test
responses to different IGRA assays [23].
However in the absence of diagnostic certainty and a
gold standard for LTBI, it remains difficult to conclu-
sively assume increased sensitivity of IGRAs compared
to TST.
The significantly decreased odds of a TSPOT.TB-ve/
TST + ve discordance in home- carers (after controlling
for HIV) is of relevance. Community health workers
comprise a large and growing population of health
workers and form the backbone of the TB control
programmes in their role as treatment and adherence
supporters through home visits, often in impoverished
settings including informal housing settlements. Drawn
from the same communities as their clients, their risk
for both TB and HIV has been shown to be greater than
that of the general population [24].
The decrease in TST-ve / IGRA+ve discordance with
duration of employment is not unexpected as increased
risk of LTBI has been associated with increased length of
employment in several studies for both IGRAs and TST
[25, 26]. The underlying mechanism of this duration
effect may be one in which IGRA is more likely than TST
to detect recent infection (involving CD4 T-cells that have
encountered antigens recently in vivo), whereas TST
detects cumulative exposure to M. tuberculosis over time
(involving CD4 T- cells of the memory phenotype)
[27, 28]. In this study BCG vaccination (as assessed
by presence of a vaccination scar) was positively asso-
ciated only with a TST + ve/TSPOT.TB- ve outcome
and not with TST + ve/QFT-ve discordance, suggesting an
effect on TST test response. This is similar to a large study
in Chinese healthcare workers, which showed higher rates
of LTBI as measured by TST in those with vaccination
scars [29]. However, not all studies have found an associ-
ation between discordance and BCG vaccination given at
birth only, with at least two reviews reporting that the
influence of BCG is relatively limited in the adult popula-
tion 10 years or more after BCG vaccination [22, 30].
There are several limitations to this study. Voluntary
participation and limited participation by clinical staff
due to high workload may have resulted in selection
bias. The high rate of indeterminate results for
TSPOT.TB also resulted in a smaller sample being avail-
able for analysis of discordance for this assay. The lack
of data on extent of immunosuppression as reflected by
CD4 is another limitation. This information could have
enhanced our understanding of the spectrum of IGRA
test response in those who are HIV infected. The use of
standardized cut-offs to denote test positivity is another
factor that may influence some of the associations
shown. The widespread use of IGRAs in serial testing
programmes have highlighted the variability of these
assays and the need for a more cautious approach to in-
terpretation of test positivity for values close to the
cut-off [31]. An exploration of different TST and IGRA
cut points may inform a more nuanced understanding of
factors associated with discordance. Lastly the lack of a
gold standard to confirm LTBI diagnosis makes it
difficult to compare test performance and arrive at con-
clusive answers in this regard.
Conclusion
In this population BCG vaccination is associated with
discordance suggesting an enduring effect for BCG given
at birth and likely impact on TST test specificity. The
markedly discordant test response in HIV infected
HCWs found in this study is compatible with potentially
greater sensitivity or reactivity of TSPOT.TB in im-
munocompromised individuals. Whilst it is known that
both IGRAs and TST are only modestly predictive of
subsequent TB risk, LTBI diagnosis and treatment
remains one of the interventions recommended by the
World Health Organization (WHO) to end the TB
epidemic worldwide [32, 33]. In high-incidence countries
it is imperative that such screening selectively and accur-
ately targets those at sufficiently high risk of progressing
to disease.
A potentially increased test sensitivity of TSPOT.TB in
a setting of a high prevalence of HIV would allow for
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more targeted IPT for those at greatest risk of progres-
sion to disease. This may enhance its potential utility in
a TB and HIV endemic setting where at least 10% of
HCWs are HIV-infected and face a six-fold higher risk
of contracting TB, as has been shown to be the case
among HCWs working in South African hospitals [34].
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